問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Hematology & Oncology

更新時間:2023-09-19

趙盈瑞
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

29Cases

2018-06-01 - 2026-08-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting1Sites

Terminated10Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2018-04-19 - 2023-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2018-10-17 - 2024-08-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-04-30 - 2026-10-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-06-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-06-01 - 2020-01-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-03-23 - 2019-03-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

李重賓
Taipei Veterans General Hospital

Digestive System Department

2020-08-01 - 2024-11-29

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-01-01 - 2026-03-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

1 2 3